Anxiolytic effects of mecamylamine in two animal models of anxiety.

10.1016/0006-2952(90)90241-C

10.1016/0014-2999(93)90498-7

10.1016/0006-3223(95)00221-9

10.1016/0006-3223(94)90060-4

10.1016/0166-4328(93)90103-W

File, 1995, Animal models of different anxiety states., Advances in Biochemical Psychopharmacology, 48, 93

10.1007/BF02246980

10.1016/S0014-2999(99)00889-4

10.1037/0735-7044.112.2.352

10.1016/S0893-133X(99)00028-7

10.1016/S0091-3057(00)00198-2

10.1037/0735-7044.112.6.1423

10.1007/BF02245751

10.1007/BF02253541

Gonzalez, 1997, A five minute experience in the elcvated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus., The Journal of Neuroscience, 17, 1505, 10.1523/JNEUROSCI.17-04-01505.1997

Martin, 1993, Central actions of nicotine antagonists., Medicinal Chemistry Research, 2, 564

10.1016/S0278-5846(00)00178-0

10.1046/j.1460-9568.1999.00823.x

10.1016/0006-8993(94)01318-C

10.1016/0006-8993(95)01359-8

10.1007/BF02245704

10.1016/0091-3057(95)02156-6

10.1016/S0006-3223(00)00945-8

Silver, 2000, Mecamylamine in Tourette's syndrome: A two-year retrospective case study., Journal of Child and Adolescent Psychopharmacology, 10, 59, 10.1089/cap.2000.10.59

Stone, 1956, Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine., Journal de Pharmacologie, 117, 169

10.1016/0091-3057(93)90492-C

Young. Mecamylamine: New therapeutic uses and toxicity/risk profile. Clinical Therapeutics 23 532 2001

10.1016/S0014-2999(00)00628-2